CELEBREX(TM) MEDIA TELECONFERENCE ADVISORY [on Jan 4, 10 A.M]
PR Wire
January 3, 1999, 7:33 p.m. ET
Celebrex(TM) Approved by Food and Drug Administration
Executives from Skokie-based G.D. Searle & Co. and New York-based Pfizer,
Inc. -- co-promoters of Celebrex(TM) (celecoxib) -- along with investigators
and patients, will discuss a new medication approved for the relief of the
signs and symptoms of osteoarthritis, and rheumatoid arthritis in adults.
On January 4th at 10:00 A.M. (CST), experts will participate in a
teleconference (to participate, dial in to 1-888-538-9956) to answer questions
and provide an overview of:
-- Celebrex clinical data
-- The science behind COX-2 inhibition
-- Celebrex pricing
-- Economic impact of arthritis
-- Patient and physician experiences
Callers will be able to participate in Q&A following the presentation.
For the first time, St. Louis-area Celebrex clinical investigators and
patients will be available for interviews after the teleconference.
CONTACT: Lori Fisher of Monsanto, 314-694-8535; or Maureen Suda of
Chandler Chicco Agency, 212-229-8448.
SOURCE G.D. Searle & Co.
-0- 01/03/99
/PRNewswire -- Jan. 03/
(PFE)
CO: G.D. Searle & Co.; Pfizer, Inc.; Monsanto
ST: New York, Missouri
IN: MTC HEA
SU: PDT
-0- Jan/03/1999 19:18
EOS (PRN) Jan/03/99 19:18 86
-0- (PRN) Jan/03/1999 19:33
More News: PFE |
